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Background: Apolipoprotein E (ApoE) participates in lipoprotein metabolism and immune regulation. This study
assessed association between ApoE polymorphisms with hyperuricemia and uric acid metabolism in Uygur men,
Xinjiang, China.
Methods: A total of 474 hyperuricemia patients and 518 healthy male controls were recruited from the Health
Screening Center, Uygur region of Xinjiang, China and subjected to ApoE genotyping using a multiplex
amplification refractory mutation system PCR.
Results: Apolipoprotein E3/3 genotype was the predominant type with a frequency of 67.7%, while E2/2 was lower
than E4/4 in Uygur males. The frequencies of ApoE2, E3, and E4 alleles were 8.5%, 80.1% and 11.4%, respectively.
Distribution of ApoE genotypes was significantly different in hyperuricemia patients from the healthy controls
(p < 0.001). Particularly, the frequency of ApoE E3/3 was 71.7%, E2/3 9.3%, E3/4 9.3%, E4/4 3.2%, E2/4 2.3%, and
E2/2 0.2% in patients vs. 68.1%, 4.6%, 2.9%, 12%, 0.6%, and 4.6% in controls, respectively. Moreover, frequency of
ApoE E2 allele was greater in the healthy controls than in patients (p < 0.001) and the highest level of uric acid
occurred in those with ApoE2/4 and E3/4 genotypes, whereas the lowest uric acid level occurred in those with
ApoE E2/2 genotype. In addition, the subjects with the ApoE2 allele had a lower uric acid and LDL-C level than
those with the ApoE3 allele and ApoE4 allele (p < 0.05). The risk of developing hyperuricemia in subjects without the
ApoE2 allele was 1.7 fold higher than those subjects with the ApoE2 allele.
Conclusions: This study revealed frequencies and distributions of ApoE alleles and genotypes in Uygur males, which
are different from Han Chinese. ApoE E4 was associated with a slightly higher risk of primary hyperuricemia, whereas
ApoE E2 was associated with reduced risk of primary hyperuricemia and LDL-C level.
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Hyperuricemia refers to an abnormally high serum level of
uric acid and commonly occurs in patients with lipoprotein
metabolism disorders, metabolic syndrome and cardio-
vascular diseases [1]. In China, the incidence of primary hy-
peruricemia in men has been reported as 21.6% (95% CI,
18.9%-24.6%) [2]. During the past decades, the mean serum* Correspondence: yaohua01@sina.com
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unless otherwise stated.uric acid levels and the prevalence of hyperuricemia in the
general population appear to be increasing, while the preva-
lence and incidence of hyperuricemia-induced gout has
doubled in the United States of America [3]. Etiologically,
many factors can contribute to hyperuricemia, such as gen-
etic susceptibility, insulin resistance, hypertension, renal in-
sufficiency, obesity, diet, and consumption of alcoholic
beverages [4]. Among these, alcohol, diet, oxidative stress,
and genetic factors play important roles in the pathogenesis
of hyperuricemia [5]. However, it remains to be defined
which genetic factors contribute to the development of
hyperuricemia.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Association of clinical data and apoE genotype








SD) (n = 474)
p-value/
Age (yrs.) 46.60 ± 11.87 47.28 ± 13.44 0.401
Stature (cm) 169.94 ± 5.11 170.28 ± 5.39 0.312
Weight (kg) 77.38 ± 9.23 80.99 ± 14.19* <0.05
BMI (kg/m2) 26.79 ± 2.96 27.88 ± 4.42* <0.001
WC (cm) 93.72 ± 8.62 97.51 ± 11.57* <0.001
Hip circumferences
(cm)
101.69 ± 7.15 102.81 ± 10.57* 0.045
WHR 0.92 ± 0.05 0.95 ± 0.07* <0.001
SBP (mmHg) 110.81 ± 16.34 118.28 ± 18.21* <0.001
DBP (mmHg) 95.81 ± 21.46 103.86 ± 23.38* <0.001
BUN (mg/dl) 5.23 ± 1.44 6.47 ± 3.57* <0.001
Cr (mg/dl) 77.44 ± 18.14 88.91 ± 35.23* 0.003
SUA (mmol/L) 308.51 ± 60.25 495.42 ± 83.66* <0.001
FBS (mmol/L) 5.18 ± 1.16 5.41 ± 1.80* 0.017
TG (mmol/L) 2.88 ± 1.76 2.75 ± 1.57* 0.005
TC (mmol/L) 4.19 ± 1.48 4.24 ± 1.41 0.594
HDL-C (mmol/L) 1.20 ± 0.43 1.13 ± 0.61* 0.043
LDL-C (mmol/L) 2.65 ± 0.88 2.74 ± 0.77 0.088
Genotype* N (%) N (%) χ2value
E2/2 24 (4.6) 1 (0.2) 0.000
E2/3 61 (11.8) 44 (9.3)
E2/4 3 (0.6) 11 (2.3)
E3/3 353 (68.1) 359 (75.7)
E3/4 15 (2.9) 44 (9.3)
E4/4 62 (12.0) 15 (3.2)
Allele 0.000
E2 112 (10.8) 57 (6.0)
E3 782 (75.7) 806 (85.0)
E4 139 (13.5) 85 (9.0)
A t-test and Pearson Chi-square (χ2) test were used to analyze the data. *The mean
difference was significant at the 0.05 level. Data are presented as range, mean ±
standard deviation, or percentage. BMI, Body Mass Index; WC, Waist Circumference;
WHR, Waist Hip Ratio; SUA, Serum Uric Acid; TG, Serum Triglyceride; TC, Serum Total
Cholesterol; HDL-C, Serum High Density Lipoprotein; LDL-C, Serum Low Density
Lipoprotein; FBS, Fasting Blood Sugar; BUN, Urea Nitrogen; SCR, Serum Creatinine.
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that plays an important role in lipoprotein metabolism
[6]. Altered expression or genetic polymorphisms was
considered as a risk factor for metabolic syndrome [7]
and more recent studies have shown that ApoE also par-
ticipates in immunoregulation by suppression of T
lymphocyte proliferation and regulation of macrophage
function [8]. ApoE may also be involved in the develop-
ment of sporadic Alzheimer disease [9-11] or other dis-
eases [12-16]. Thus, ApoE has become a focus for
investigation of its role in metabolic diseases. For ex-
ample, previous studies showed that in the pathogenesis
of hyperuricemia, ApoE polymorphisms in patients with
gout were reported to be associated with reduced renal
excretion of urates [17,18].
ApoE is mapped to chromosome 19 (19q13.2) [19] and
contains four exons. ApoE polymorphisms affect three
common alleles (designated E2, E3, and E4). ApoE E3
allele has a cysteine at position 112 and an arginine at
158, while ApoE E4 has an arginine at position 112,
and ApoE E2 has a cysteine at position 158. Although
there are just one or two amino acid changes, these
ApoE polymorphisms alter ApoE structure and func-
tion [20]. In the general population, the prevalence of
ApoE2 is between 0.01 and 0.15, ApoE3 between 0.49
and 0.91, and ApoE4 is between 0.06 and 0.37 [15].
ApoE3 most commonly occurs in humans and is found
in more than half of the general population [21]. How-
ever, distribution of ApoE genotypes differs among
populations [6]. Thus, in this study, we aimed to detect
the frequency of ApoE polymorphisms in Uygur males
and assess how ApoE polymorphisms were associated
with primary hyperuricemia risk.
Results
Characterization of study population
Summary statistics of characterizations are shown in
Table 1. The data showed that body weight and BMI of
hyperuricemia patients were smaller than that of
healthy controls (p < 0.05). Most of the blood tests
were abnormal in patients, whereas all were normal in
the healthy controls (Table 1).
Comparison of ApoE allele frequencies and genotype
distribution in hyperuricemia with male Uygur controls
The distribution of ApoE genotypes was consistent
with the Hardy-Weinberg equilibrium. The frequen-
cies of ApoE2, E3 and E4 were approximately 8.5%,
80.05%, and 11.45% in these studied subjects, respect-
ively. Table 1 and Figure 1A showed the distribution
of ApoE genotypes differed between hyperuricemia and
control subjects in Uygur men (χ2 = 69.662, P = 0.000). The
most common genotype in the hyperuricemia group was
E3/3 (71.7%), followed by E2/3 (9.3%), E3/4 (9.3%), E4/4(3.2%), E2/4 (2.3%), and E2/2 (0.2%), whereas those in
control subjects were E3/3 (68.1%), followed by E4/4
(12%), E2/3 (11.8%), E2/2 (4.6%), E3/4 (2.9%), and E2/
4 (0.6%). Furthermore, Table 1 and Figure 1B showed
the distribution of ApoE alleles was different between
hyperuricemia and control (χ2 = 27.684, P = 0.000).
Thus, the frequency of the ApoE2 allele in control
subjects (10.8%) was greater than in the hyperuricemic







































Figure 1 Frequency of ApoE genotypes and alleles in hyperuricemia patients and controls. A, Genotypes and B, Alleles.
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incidence among the different ApoE genotypes and
alleles
These ApoE genotypes were associated with the highest
level of uric acid and hyperuricemia incidence (p <
0.001). Specifically, the subjects with an ApoE2/4 geno-
type had a higher level of serum uric acid and risk indeveloping hyperuricemia, followed by ApoE3/4, E3/3,
E2/3, and E4/4. However, subjects with the ApoE2/2
genotype had the lowest level of serum uric acid level
and a lower hyperuricemia incidence (Table 2, Figure 1A,
Figure 2A, and Figure 3A).
However, the subjects without the ApoE2 allele had a
higher uric acid level than those with the ApoE2 allele
Table 2 Association of ApoE genotypes with serum uric
acid level and hyperuricemia patients and controls
Genotypes N SUA level Hyperuricemia patients Controls
Mean ± SD N (%) N (%)
E2/2 25 318.52 ± 72.29 1(4.0) 24(96.0)
E3/3 712 407.32 ± 119.78 359(50.4) 353(49.6)
E4/4 77 324.74 ± 83.67 15(19.5) 62(80.5)
E2/3 105 380.85 ± 104.21 44(41.9) 61(58.1)
E3/4 59 425.24 ± 110.52 44(74.6) 15(25.4
E2/4 14 469.87 ± 165.93 11(78.6) 3(21.4)
Total 992 397.82 ± 118.15 474(47.8) 518(52.2)
F value/χ2 11.784 69.662
p value <0.001 < 0.001
**One-way analysis of variance (ANOVA) was used to analyze the differences.
**Pearson Chi-square (χ2) test was used to analyze the differences. SUA, serum
uric acid.
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the incidence of hyperuricemia was also higher in sub-
jects without the ApoE2 allele (p < 0.001) and the risk
of developing hyperuricemia was 1.7 fold higher than
those subjects with the ApoE2 allele. Moreover, com-
pared to the subjects with the ApoE4 allele, serum uric
acid levels in the subjects without the ApoE4 allele was
higher (p < 0.05; Table 3), but did not augment the risk of
developing hyperuricemia (p > 0.05).
Moreover, we also compared other biochemical pa-
rameters with different ApoE genotypes between hyper-
uricemia patients and controls and found that both
groups of subjects with the ApoE2 allele had a lower uric
acid and LDL-C level than those with the ApoE3 allele
and ApoE4 allele (p <0.05; Table 4).
Discussion
The distribution of ApoE genotypes and alleles varies
among different races and geographic areas [22]. In gen-
eral, the frequency of ApoE E3/3 is higher (>60%) than
that of other genotypes, whereas ApoE4/4, E2/4 and E2/
2 have the lowest frequency. In China, the frequency of
the ApoE3 allele is approximately 85.2%, which is higher
than that of the Caucasian population (76.9%), whereas
the ApoE4 allele is about 6.4%, which is obviously lower
than that of the Caucasian population (14.3%) [23]. In
the current study, we found that the distribution of the
ApoE3 allele in Uygur males was over 80%, which is be-
tween that found in the Chinese and Caucasian popula-
tions. Our data may suggest the Uygur as a separate
ethnic group in its own right. Indeed, a previous study
of the origin of Human species utilized DNA sequencing
technology to assess the Uygur mummy unearthed
3,000 years ago from a dry desert in the Tarim region of
Xinjiang, China and showed that the Xinjiang Uygur
ethnic originated from Europe [24,25]. Our current dataon the ApoE polymorphism may provide additional evi-
dence. However, after approximately 3000 years of evo-
lution, one may expect that the ApoE3 allele may be
also changed.
ApoE protein is a major component in the very-low-
density lipoprotein (VLDL) and the latter helps to re-
move excess cholesterol from the blood and carry it to
the liver for metabolism. ApoE protein also helps to
clearance chylomicrons and VLDL from the bloodstream
and acts as a ligand to bind to the hepatic receptors, in-
cluding the low-density lipoprotein (LDL) receptor, LDL
receptor–related protein, and VLDL receptor. ApoE2
and E4 are functionally and metabolically different from
the common form of ApoE3. For example, ApoE2 has
poor affinity to the hepatic lipoprotein receptor, result-
ing in decreased catabolism of triglyceride-rich lipopro-
teins and accumulation of VLDL and chylomicron
remnants in the blood [13], whereas ApoE4 is associated
with the increased clearance of these lipoproteins, result-
ing in hypercholesterolemia and elevated levels of LDL
[6]. In the current study, we also compared other meta-
bolic indicators that connected lipid metabolism with
renal functions between different ApoE genotypes in hy-
peruricemia patients and controls and found both
groups of subjects with the ApoE2 allele had a lower
LDL-C level than those with the ApoE3 allele and ApoE4
allele, while the subjects with the ApoE4 allele had the
highest LDL-C level than other groups, which was con-
sistent with other studies [6].
The possible association of ApoE and risk of hyperuri-
cemia has been widely investigated in different popula-
tions [21]. However, to date, there is no study on the
under-represented Uygur in Xinjiang. In the current
study, we aimed to understand the possible association
of ApoE with risk of hyperuricemia in Uygur population.
Our data showed that although ApoE 3/3 genotype is
the most common genotype in Uygur, the frequency of
E2/2 genotype is lower than the E4/4 genotype in both
control and hyperuricemia subjects. The frequency of
The frequency of The frequency of indicating that
ApoE2 may have a protective function for primary
hyperuricemia.
Previous studies of different populations showed that
the incidence of primary hyperuricemia has increased
significantly in recent years and that the onset tends to
occur at younger age [1]. Clinically, hyperuricemia is
closely related to obesity, hyperlipidemia, hypertension,
diabetes, atherosclerosis and other diseases [26]. It has
been noted that the ApoE gene polymorphism plays a
role in the development of gout, primary hyperuricemia,
and hypertriglyceridemia. For example, Moriwaki et al.
[27] reported that the frequency of ApoE4 was higher in
patients with gout and hypertriglyceridemia than those
with hypertriglyceridemia alone. Furthermore, besides
Figure 2 Association of ApoE genotypes and alleles with serum level of uric acid. A, Genotypes and B, Alleles.
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also increase incidence of hypertriglyceridemia in pa-
tients with gout, thus being a risk factor for athero-
sclerosis in gout patients. Cardona et al. [17]
investigated the correlation between ApoE allele and
renal excretion of urate in 68 gout patients and 50
normal controls and found that in gout patients with
ApoE2, the levels of TG and VLDL were significantly
higher but the renal excretion of urates was decreased.
They concluded that the reduction of renal excretion
of urates was mediated by the high level of VLDL andApoE2. Uygur ethnics are a special population in
Xinjiang, China, which live in a dry and hot area; thus,
they have different lifestyles and food consumption
from other provinces in China. Their diet contains
high-fat, high protein, and sugar, but little fish and
vegetables. Obesity in the urban Uygar population is
high. All of these may contribute to primary hyperuri-
cemia, hypertension, diabetes, and other metabolic
diseases. Our current study showed that frequencies of
the ApoE genotype and alleles were unique in this
























Figure 3 Association of ApoE genotypes and alleles with risk of hyperuricemia. A, Genotypes and B, Alleles.
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by Moriwaki [27], Elmadbouh et al. [28] and others
[29]. Furthermore, our current study also showed that
the SUA level in the male Uygur was statistically sig-
nificant between different genotypes i.e. subjects with
ApoE2/4 and E3/4 genotype were associated with a
higher SUA level and hyperuricemia risk, which is also
consistent with the data reported by Cardona et al.
[7,23]. It has been noted that the ApoE polymorphism
was associated with development of gout and primaryhyperuricemia. However, Moriwaki et al. [30] analyzed
221 male gout patients and 141 male controls and
found that there was no statistically significant differ-
ence in frequencies of ApoE allele (E2, E3, or E4) be-
tween gout patients and hyperuricemia, and the
healthy controls.
Conclusions
The distribution of ApoE alleles and genotype frequen-
cies in the Uygur male is unique, and was associated
Table 3 Association of the mean SUA level and hyperuricemia incidence between the subjects with and without ApoE2 and
E4 allele
E2 allele(n = 130) w/o E2 allele(n = 862) P value OR
SUA level (Mean ± SD) 368.86 ± 101.6 402.19 ± 119.8 0.003
Hyperuricemia (%) 34.6 49.8 0.000 1.728
E4 allele(n = 147) w/o E4 allele(n = 845) P value OR
SUA level (Mean ± SD) 379.35 ± 118.2 401.03 ± 117.9 0.040
Hyperuricemia (%) 47.6 47.8 0.966 1.007
Pearson’s chi-square test was used to analyze the data. *The mean difference was significant at the 0.05 level. w/o, Without. OR, Relative risk.
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slight increased risk of primary hyperuricemia, whereas
ApoE E2 was associated with protection against primary
hyperuricemia and LDL-C in Uygur men in China. How-
ever, our current study is just proof-of-principle and
much more data are needed to confirm the link of ApoE
polymorphisms with the risk of primary hyperuricemia.
Methods
Participants and study design
This case–control study recruited 992 subjects selected
from the Affiliated Hospitals of Xinjiang Medical University
(Uygur, China). They were all from Uygur and the
cases contained 474 patients with hyperuricemia, con-
firmed by laboratory tests (serum uric acid levels wereTable 4 Comparison of the biochemical parameters between
controls
Groups Variable(s) ApoE2 (85) ApoE3 (35
control group BUN (mg/dl) 5.15 ± 1.42 5.23 ± 1.46
Cr (mg/dl) 75.54 ± 15.60 76.99 ± 18
SUA (mmol/L) 287.93 ± 57.89 312.24 ± 5
FBS(mmol/L) 5.29 ± 1.35 5.19 ± 1.18
TG(mmol/L) 2.13 ± 1.52 2.58 ± 1.8
TC(mmol/L) 4.17 ± 1.38 4.20 ± 1.50
HDL-C(mmol/L) 1.14 ± 0.44 1.22 ± 0.45
LDL-C(mmol/L) 2.45 ± 0.63 2.81 ± 0.82
Groups Variable(s) ApoE2 (45) ApoE3 (359
BUN (mg/dl) 5.74 ± 2.29 6.51 ± 3.44
Cr (mg/dl) 79.64 ± 30.99 87.13 ± 25
Hyperuricemia patients SUA (mmol/L) 473.29 ± 55.02 476.53 ± 7
FBS(mmol/L) 5.38 ± 2.07 5.39 ± 1.69
TG(mmol/L) 2.44 ± 1.13 2.77 ± 1.0
TC(mmol/L) 4.29 ± 1.54 4.16 ± 1.39
HDL-C(mmol/L) 1.23 ± 0.87 1.12 ± 0.55
LDL-C(mmol/L) 2.33 ± 1.00 2.71 ± 0.82
A t-test was used to analyze the data. *The mean difference was significant at the 0
ApoE3 subjects. pb, p values that were obtained when comparing subjects with Apo
with ApoE2 subjects. ApoE4.
(1) ApoE3 group (subjects carrying the E3/3 genotype), (2) ApoE2 group (subjects ca
or E3/4 genotype). Subjects with the E2/4 genotype (n = 14) were excluded from th
lipid levels.more than 417 μM), whereas the gender and age-
matched healthy control subjects had no history of hy-
peruricemia. This study was approved by the Ethics
Committee of the First Affiliated Hospital of Xinjiang
Medical University and was conducted according to
the standards of the Declaration of Helsinki. All par-
ticipants were fully informed of the purpose of this
study and all subjects provided written informed con-
sent before enrollment into the study.Inclusion and exclusion criteria
We recruited Uygur men aged between 18 to 70 years as
the hyperuricemia group, who had serum uric acid levels
more than 417 μmol within 2 weeks before entering thisdifferent ApoE alleles in hyperuricemia patients and
3) ApoE4 (77) Total (478) pa pb pc
5.30 ± 1.44 5.22 ± 1.45 0.675 0.682 0.516
.88 80.53 ± 16.74 77.36 ± 18.12 0.523 0.107 0.080
9.89 311.86 ± 61.03 308.54 ± 60.30 0.001* 0.958 0.011*
5.03 ± 0.82 5.18 ± 1.16 0.480 0.260 0.149
2.29 ± 1.59 2.46 ± 1.77 0.037* 0.188 0.578
4.15 ± 1.54 4.19 ± 1.48 0.863 0.791 0.936
1.20 ± 0.34 1.20 ± 0.44 0.158 0.825 0.364
2.78 ± 0.67 2.75 ± 0.78 0.000* 0.710 0.008*
) ApoE4 (59) Total (463) pa pb pc
6.20 ± 2.16 6.39 ± 3.21 0.135 0.503 0.470
.21 90.17 ± 37.16 88.76 ± 35.37 0.060 0.540 0.285
1.12 500.82 ± 85.37 494.95 ± 81.42 0.840 0.058* 0.016*
5.39 ± 2.17 5.39 ± 1.79 0.938 0.999 0.950
2.71 ± 1.4259 2.73 ± 1.53 0.168 0.775 0.369
4.54 ± 1.21 4.22 ± 1.39 0.532 0.047* 0.363
1.14 ± 0.64 1.13 ± 0.60 0.221 0.810 0.419
2.72 ± 1.00 2.67 ± 0.87 0.006* 0.929 0.023*
.05 level. pa, p values that were obtained when comparing ApoE2 subjects with
E3 subjects. ApoE4. pc, p values that were obtained when comparing subjects
rrying the E2/2 or E2/3 genotype), (3) ApoE4 group (subjects carrying the E4/4
e extra analyses because of the opposite effects of the E2 and E4 alleles on the
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uricemia group for age and gender. The exclusion cri-
teria were i) acute onset of gouty arthritis or renal stone;
ii) significant liver or renal dysfunction, hematological
disease, oncological disease, or other life threatening dis-
orders; iii) conditions that need the management of di-
uretics or analgesic agents; and iv) receiving any anti-
hyperuricemia agents.
Date collection and blood tests
A questionnaire was used to collected data on the demo-
graphic, lifestyle, and disease history from all partici-
pants. Physical examination was also performed on all
participants, including height (measured in centimeter
for an error less than 0.5 cm), bodyweight (measured in
kilogram for an error less than 0.1 kg), body mass index
(BMI), waist circumference (WC), and hip circumfer-
ence (calibrated weekly to within 1 mm using plastic
tapes), blood pressure and blood tests (see below). The
waist circumference was measured at the end of a gentle
expiration midway between the lowest rib and iliac crest,
with the study participant standing, while the hip cir-
cumference was measured at the greater trochanter. The
waist hip ratio (WHR) was determined as waist (cm) di-
vided by hip (cm). Blood pressure was measured using
the automatic clinical blood pressure monitor three
times in the sitting position following a standard proto-
col. All participants were at rest at least 10 min before
the physical examination.
All participants were also asked to fast for at least 12 h
and not to consume any alcohol or high-fat foods on the
previous night before blood withdrawal the next morn-
ing. Each subject had two mL of venous blood with-
drawn to assess serum uric acid (SUA), triglyceride
(TG), total cholesterol (TC), high-density lipoprotein
(HDL-C), low-density lipoprotein (LDL-C), fasting blood
sugar (FBS), urea nitrogen (BUN), and creatinine (SCR),
measured by the 7060 Automatic Biochemical Analyzer
(Hitachi, Ltd., Tokyo, Japan).
Genomic DNA extraction and ApoE genotyping
Genomic DNA was extracted from blood cells by the
salting-out method [31,32] and subjected to ApoE geno-
typing using Gerard’s method with modifications in the
multiplex amplification refractory mutation system PCR
(Multi-ARMS PCR) [30,33]. The primers were designed
and synthesized by the Biological Products Engineering
Co., Ltd. (Shanghai, China) for ApoE (5'-GTTCAGTGA
TTGTCGCTGGGCA-3' that paired with Arg/Cyys158/
Arg158 (5'-ATGCCGATGACCTGCAGAATT-3' or 5'-AT
GCCGATGACCTGCAGAATC-3'), Cys112/Arg112 (5'-CG
CGGACATGGAGGACGTTT-3' or 5'-CGCGGACATGG
AGGACGTTC-3'). A common primer was ds 158 or Arg/
Cys 112 and produced an amplicon of 588 bp and 451 bp,respectively. The PCR mixture in 25 μL contained 50 ng of
genomic DNA, 200 μmol/L of dNTPs (Biological Products
Engineering Co., Ltd), PCR buffer with 10 mmol/L Tris–
HCl, pH 8.8, 1.5 mmol/L MgCl2, 50 mmol/L KCl, and
1 mL/L Triton X-100 from Finnzymes (Shanghai, China),
80 g/L dimethyl sulfoxide (DMSO; Sigma), 1 U of DyNA-
zyme II DNA Polymerase (Finnzymes), 8 nmol/L of α1-
antitrypsin primers, and 0.8 μmol/L ARMS common pri-
mer. The reaction mixture A in addition to the above also
contained 0.8 μmol/L Cys158 and 0.4 μmol/L Cys112
primers. Similarly, the reaction mixture B contained
0.8 μmol/L Arg158 and 0.4 μmol/L Arg112 primers. The
PCR amplification was set to an initial denaturation at 95°C
for 4 min and then 35 cycles of 96°C for 45 s, 66°C for 45 s,
and 72°C for 45 s, and followed by a final extension at 72°C
for 5 min. The PCR product (9 μL) was mixed with 3 μL of
6 × gel loading dye type I (Sigma) and separated on a 1.6%
agarose gel (Sigma) that contained 0.1 mg/L ethidium
bromide (Bio-Rad, Hercules, CA, USA).
Statistical analysis
The data are summarized as numbers, percentage, or
mean ± standard deviation and then organized in Epidata
3.0 software (The EpiData Association, Odense,
Denmark) and analyzed by using SPSS 16.0 for windows
software package (SPSS, Chicago, IL, USA). Simple de-
scriptive statistics were used to describe the variables
among the participants. The differences of measure-
ments from different groups were compared with stu-
dent t-test and One-way analysis of variance (ANOVA).
ApoE genotypes and frequencies were analyzed with
Pearson’s chi-square test, if genotypes met the Hardy-
Weinberg equilibrium. A p value < 0.05 was considered
to be statistically significant.
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